OCUL
Price
$7.71
Change
-$0.19 (-2.41%)
Updated
Apr 25 closing price
Capitalization
1.23B
15 days until earnings call
VRDN
Price
$13.50
Change
-$0.06 (-0.44%)
Updated
Apr 25 closing price
Capitalization
1.1B
10 days until earnings call
Ad is loading...

OCUL vs VRDN

Header iconOCUL vs VRDN Comparison
Open Charts OCUL vs VRDNBanner chart's image
Ocular Therapeutix
Price$7.71
Change-$0.19 (-2.41%)
Volume$1.71M
Capitalization1.23B
Viridian Therapeutics
Price$13.50
Change-$0.06 (-0.44%)
Volume$524.68K
Capitalization1.1B
OCUL vs VRDN Comparison Chart
Loading...
OCUL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VRDN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
OCUL vs. VRDN commentary
Apr 27, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is OCUL is a StrongBuy and VRDN is a Buy.

Ad is loading...
COMPARISON
Comparison
Apr 27, 2025
Stock price -- (OCUL: $7.71 vs. VRDN: $13.50)
Brand notoriety: OCUL and VRDN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: OCUL: 102% vs. VRDN: 56%
Market capitalization -- OCUL: $1.23B vs. VRDN: $1.1B
OCUL [@Biotechnology] is valued at $1.23B. VRDN’s [@Biotechnology] market capitalization is $1.1B. The market cap for tickers in the [@Biotechnology] industry ranges from $276.16B to $0. The average market capitalization across the [@Biotechnology] industry is $2.14B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

OCUL’s FA Score shows that 0 FA rating(s) are green whileVRDN’s FA Score has 0 green FA rating(s).

  • OCUL’s FA Score: 0 green, 5 red.
  • VRDN’s FA Score: 0 green, 5 red.
According to our system of comparison, OCUL is a better buy in the long-term than VRDN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

OCUL’s TA Score shows that 6 TA indicator(s) are bullish while VRDN’s TA Score has 5 bullish TA indicator(s).

  • OCUL’s TA Score: 6 bullish, 3 bearish.
  • VRDN’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, OCUL is a better buy in the short-term than VRDN.

Price Growth

OCUL (@Biotechnology) experienced а +5.47% price change this week, while VRDN (@Biotechnology) price change was +2.82% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +8.19%. For the same industry, the average monthly price growth was -3.08%, and the average quarterly price growth was -10.41%.

Reported Earning Dates

OCUL is expected to report earnings on Aug 11, 2025.

VRDN is expected to report earnings on Aug 06, 2025.

Industries' Descriptions

@Biotechnology (+8.19% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
OCUL($1.23B) has a higher market cap than VRDN($1.1B). OCUL YTD gains are higher at: -9.719 vs. VRDN (-29.577). OCUL has higher annual earnings (EBITDA): -176.14M vs. VRDN (-266.36M). VRDN has more cash in the bank: 718M vs. OCUL (392M). VRDN has less debt than OCUL: VRDN (21.1M) vs OCUL (75.8M). OCUL has higher revenues than VRDN: OCUL (63.7M) vs VRDN (302K).
OCULVRDNOCUL / VRDN
Capitalization1.23B1.1B111%
EBITDA-176.14M-266.36M66%
Gain YTD-9.719-29.57733%
P/E RatioN/AN/A-
Revenue63.7M302K21,093%
Total Cash392M718M55%
Total Debt75.8M21.1M359%
FUNDAMENTALS RATINGS
OCUL vs VRDN: Fundamental Ratings
OCUL
VRDN
OUTLOOK RATING
1..100
227
VALUATION
overvalued / fair valued / undervalued
1..100
51
Fair valued
92
Overvalued
PROFIT vs RISK RATING
1..100
8374
SMR RATING
1..100
9594
PRICE GROWTH RATING
1..100
4764
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

OCUL's Valuation (51) in the Pharmaceuticals Other industry is somewhat better than the same rating for VRDN (92) in the Biotechnology industry. This means that OCUL’s stock grew somewhat faster than VRDN’s over the last 12 months.

VRDN's Profit vs Risk Rating (74) in the Biotechnology industry is in the same range as OCUL (83) in the Pharmaceuticals Other industry. This means that VRDN’s stock grew similarly to OCUL’s over the last 12 months.

VRDN's SMR Rating (94) in the Biotechnology industry is in the same range as OCUL (95) in the Pharmaceuticals Other industry. This means that VRDN’s stock grew similarly to OCUL’s over the last 12 months.

OCUL's Price Growth Rating (47) in the Pharmaceuticals Other industry is in the same range as VRDN (64) in the Biotechnology industry. This means that OCUL’s stock grew similarly to VRDN’s over the last 12 months.

OCUL's P/E Growth Rating (100) in the Pharmaceuticals Other industry is in the same range as VRDN (100) in the Biotechnology industry. This means that OCUL’s stock grew similarly to VRDN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
OCULVRDN
RSI
ODDS (%)
N/A
Bullish Trend 2 days ago
83%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
81%
Bearish Trend 2 days ago
85%
Momentum
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
81%
MACD
ODDS (%)
Bullish Trend 2 days ago
73%
Bullish Trend 2 days ago
78%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
79%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
87%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 5 days ago
80%
Bullish Trend 13 days ago
80%
Declines
ODDS (%)
Bearish Trend 11 days ago
84%
Bearish Trend 11 days ago
86%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
77%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Ad is loading...
OCUL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VRDN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
ARGFX62.020.11
+0.18%
Ariel Fund Investor
SSCGX31.380.01
+0.03%
SEI Small Cap Growth F (SIMT)
BSMIX15.12N/A
N/A
iShares Russell Small/Mid-Cap Idx Instl
KNGIX11.28-0.07
-0.62%
Vest S&P500 Div Aristocrats Trgt Inc Ins
TRUZX50.60-0.33
-0.65%
T. Rowe Price New Horizons Z

OCUL and

Correlation & Price change

A.I.dvisor indicates that over the last year, OCUL has been loosely correlated with EYPT. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if OCUL jumps, then EYPT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To OCUL
1D Price
Change %
OCUL100%
-2.41%
EYPT - OCUL
54%
Loosely correlated
-2.60%
ELVN - OCUL
50%
Loosely correlated
-0.49%
DNLI - OCUL
48%
Loosely correlated
+1.23%
BHVN - OCUL
48%
Loosely correlated
-15.21%
VRDN - OCUL
46%
Loosely correlated
-0.44%
More

VRDN and

Correlation & Price change

A.I.dvisor indicates that over the last year, VRDN has been loosely correlated with DNLI. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if VRDN jumps, then DNLI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VRDN
1D Price
Change %
VRDN100%
-0.44%
DNLI - VRDN
50%
Loosely correlated
+1.23%
AURA - VRDN
47%
Loosely correlated
-2.54%
OCUL - VRDN
46%
Loosely correlated
-2.41%
TERN - VRDN
45%
Loosely correlated
-4.26%
CCCC - VRDN
45%
Loosely correlated
-4.35%
More